Use of tissue micro array (TMA) in routine clinical analysis

Similar documents
Central Pathology Review and Tissue MicroArrays. Dr Lisa Storer Children s Brain Tumour Research Centre Nottingham

The following slides were presented at the TIGA Workshop, and are enclosed in the PP show format (*.pps) in order to include all presented details.

Optimal algorithm for HER2 testing

Image analysis in IHC overview, considerations and applications

Quality Assurance and Quality Control in the Pathology Dept.

NSABP B-55/BIG Lynne Suhayda, RN, MSEd. Director, Clinical Coordinating Department. NRG Oncology - Pittsburgh, Pennsylvania

Quality assurance and quality control in pathology in breast disease centers

Inti Zlobec 1*, Viktor H Koelzer 1,2, Heather Dawson 1,2, Aurel Perren 1,2 and Alessandro Lugli 1,2

Digital Pathology Diagnosis Assistance System

CANCER. Clinical Validation of Breast Cancer Predictive Markers

HER2 FISH pharmdx TM Interpretation Guide - Breast Cancer

07/06/2013. Commentary. The best way to achieve optimal treatment of today s patients is to ensure the availability of

Tissue microarray TMA

Workflow. Connecting the Pieces For Total Patient Care

Next generation image analysis for immunohistochemistry quantitation

Breast Cancer Diversity Various Disease Subtypes Clinical Diversity

CC01 - Colon Cancer Tissue Microarray

Veridiam Tissue Arrayer

NordiQC External Quality Assurance in Immunohistochemistry

FAQs for UK Pathology Departments

Utility of Adequate Core Biopsy Samples from Ultrasound Biopsies Needed for Today s Breast Pathology

Supplementary Appendix

Kristen E. Muller, DO, Jonathan D. Marotti, MD, Vincent A. Memoli, MD, Wendy A. Wells, MD, and Laura J. Tafe, MD

Gaining New Insights Through IF Multiplexed Staining and Analysis. Tyna Hope, Ph.D. P.Eng Biomarker Imaging Research Laboratory October 5, 2017

Minimizing Errors in Diagnostic Pathology

BREAST CANCER PATHOLOGY

Androgen Receptor Expression in Renal Cell Carcinoma: A New Actionable Target?

Giuseppe Viale for the BIG 1 98 Collaborative and International Breast Cancer Study Groups

HER2 status assessment in breast cancer. Marc van de Vijver Academic Medical Centre (AMC), Amsterdam

Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies

Immunohistochemical classification of breast tumours

Layered-IHC (L-IHC): A novel and robust approach to multiplexed immunohistochemistry So many markers and so little tissue

Visual interpretation in pathology

Personalized Medicine Disruptive Technology? David Logan Senior Vice President, Commercial Genomic Health Inc

The use of diagnostic FFPE material in cancer epidemiology research

Guideline. Associated Documents ASCO CAP 2018 GUIDELINES and SUPPLEMENTS -

Dr. dr. Primariadewi R, SpPA(K)

Next-Gen Analytics in Digital Pathology

Clinical utility of cancer biomarkers assessed by virtual microscopy

LN04 - Lymphoma Tissue Microarray

Case Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions.

Adjuvan Chemotherapy in Breast Cancer

Welcome. Nanostring Immuno-Oncology Summit. September 21st, FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.

Template for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of the Breast

Quality in Control. ROS1 Analyte Control. Product Codes: HCL022, HCL023 and HCL024

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY

Data Science Reduces Anatomic Pathology Reporting Errors

# Best Practices for IHC Detection and Interpretation of ER, PR, and HER2 Protein Overexpression in Breast Cancer

Contemporary Classification of Breast Cancer

W3C Life Sciences: Clinical Observations Interoperability: EMR + Clinical Trials Use-case for EMR + Clinical Trials Interoperability

Breast cancer diagnostic solutions Deliver diagnostic confidence

Cancer Screening Program in GEORGIA

October Billing and compliance. Coagulation. Immunohistochemistry. Immunology. Referral testing ICD 10

Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Pathology. AGO e. V. in der DGGG e.v. sowie in der DKG e.v.

Dako IT S ABOUT TIME. Interpretation Guide. Agilent Pathology Solutions. ALK, ROS1 and RET IQFISH probes (Dako Omnis) MET IQFISH probe (Dako Omnis)

Examples of Nordic collaborations: benefits and challenges

Three Hours Thirty Minutes

A Study to Evaluate the Effect of Neoadjuvant Chemotherapy on Hormonal and Her-2 Receptor Status in Carcinoma Breast

COMPUTER-AIDED HER-2/neu EVALUATION IN EXTERNAL QUALITY ASSURANCE (EQA) OF BREAST CANCER SCREENING PROGRAMME

Your Guide to the Breast Cancer Pathology. Report. Key Questions. Here are important questions to be sure you understand, with your doctor s help:

Cost Effectiveness of Manual Tissue Microarray Technique in Diagnostic Immunohistochemistry

My Personalized Breast Cancer Worksheet

What is Tuberous Sclerosis Complex?

Breast cancer pathology

Guideline for the Diagnosis of Breast Cancer

Product Introduction. Product Codes: HCL029, HCL030 and HCL031. Issue

T he HER2/neu type 1 tyrosine kinase growth factor

Interpreting Therapeutic Response on Immune Cell Number and Spatial Distribution within the Tumor Microenvironment. Lorcan Sherry, CSO OracleBio

Supplementary Information

IT S ABOUT TIME. IQFISH pharmdx Interpretation Guide THREEHOURSTHIRTYMINUTES. HER2 IQFISH pharmdxtm. TOP2A IQFISH pharmdxtm

GOALS AND OBJECTIVES BREAST PATHOLOGY

What is HER2 positive breast cancer in 2018? Updated ASCO-CAP guidelines. Giuseppe Viale University of Milan European Institute of Oncology

Version 2 of these Guidelines were drafted in response to published updated ASCO/CAP HER2 test Guideline Recommendations-

1. Q: What has changed from the draft recommendations posted for public comment in November/December 2011?

Profili di espressione genica

Importance of Methodology Certification and Accreditations to Perform Assays. Stan Hamilton, MD Head, Pathology and Laboratory Medicine

AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits

So, we already talked about that recognition is the key to optimal treatment and outcome.

The Danish Blood Donor Study - Platform and results

Hans Erik Henriksen, CEO Healthcare DENMARK

RNA preparation from extracted paraffin cores:

Mamma Centrum / Zelený Pruh - Prague, Czech Republic

2015 Public Outcomes Report Cancer Program Practice Profile Reports 2013 Breast and Colon Cancer

Cork University Hospital - Cork, Ireland

Alexandrovska Hospital - Sofia, Bulgaria

HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer

Product Introduction

Nationwide Children s Hospital Biospecimen Core Resource Training

Prognostic and Predictive Factors

Clinical Utility of Diagnostic Tests

Groote Schuur Academic Hospital - Cape Town, South Africa

MEDICAL POLICY. Proprietary Information of Excellus Health Plan, Inc. A nonprofit independent licensee of the BlueCross BlueShield Association

Journal of Breast Cancer

UK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin

HER2 CISH pharmdx TM Kit Interpretation Guide Breast Cancer

Breast cancer: IHC classification. Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark

Cytogenetics 101: Clinical Research and Molecular Genetic Technologies

UCL-Advanced Diagnostics. 2015/16 Service Update

Transcription:

2nd European Workshop on Tissue Imaging and Analysis June 25-26, 2010 Use of tissue micro array (TMA) in routine clinical analysis Tim Svenstrup Poulsen Molecular unit Dept. pathology Herlev Hospital Denmark

Cancer and cancer-related treatment Figure. Number of persons, received a cancer or cancer related treatment, 2001 2008, 1.000 CHALLENGE: Financial crisis Increasing proportion of population will be in cancer treatment New medical treatments National integrated cancer pathways (waiting time and survival rates) Implementing molecular analysis of biomarkers

Denmark Population 5.5 millions Jutland, Funen, Zealand Health service is financed by a national 8% tax 1/3 of the Danish population is living in the capital (Copenhagen) or in the suburbs of Copenhagen Figure. Map of Denmark with the 6 national CancerBiobank key hospitals

Danish CancerBiobank Danish CancerBiobank is funded by the government (www.danskcancerbiobank.dk) Danish CancerBiobank is archiving cancer tissue and blood samples from patients All patients are asked to enroll Based on unique national Danish, social security number Figure. Map of region H

Central Danish CancerBiobank Hospitals get paid by the government per sample sent to the Danish CancerBiobank The Danish National Board of Health, is collecting journals of all persons in contact with the Danish health care system and all newly diagnosed cancer patients Herlev Hospital is home of the Danish CancerBiobank

Central Danish CancerBiobank Blod samples Tissue samples 14 days Referral First visit Biopsy/ Treatment Surgery Consent The Danish National Board of Health

Collecting all cancers cases BioBank center preparations Cancer Copenhagen 3.484 Herlev 3.433 Naestved 2.263 Odense 4.475 Aarhus 4.574 Aalborg 2.344 Total 21.573 Skin 1.250 Colon 4.000 Lung 4.000 Mama 4.500 Prosteta 3.500 Other 4.000 Total 21.500

Selection of cancer area Examine H&E staining Select the right tumor area for tissue micro array (TMA) Prepare TMA block(s) two times per week Today on slide - in future on digital image Figure. Digital image of H&E staining of a breast cancer section, captured on a NanoZoomer 2.0

Present: Tissue micro array High throughput Formalin fixed paraffin embedded (FFPE) blocks Core punches diameter 2 mm Fast Manuel paper work Fig. ATA-100 TMA, reliable old fashion

Coming: Tissue micro array Electronic documentation Walk away 26 cores per TMA QC Fig. ATA-27 TMA, from Beecher with a transfer capacity of 26 cores from different donor blocks to each recipient block.

Use of Tissue micro array Whole slide: typically one (1) patient sample per slide TMA: Current method 25 patient samples per slide This will lower the price per test ~20x Figure. Slide with 99 different cancer tissue

Multiple use of TMA slides TMA can be used for a range of molecular analyses: H&E IHC FISH ISH Typically used for analysis of biomarkers

Mamma panel HER2 IHC (Herceptin) ER IHC (Hormonal therapy*) PGR IHC (Hormonal therapy*) KI-67 IHC (Prognostic) TOP2A FISH (Anthracyclin) ERRB2 FISH (Herceptin) *Tamoxifen or aromatase inhibitors Figure. Breast canncer tissue with biomarker HER2 gene copy number change. Treatment with herceptin is only effective in amplified cases. Only 20% of all breast cancers are HER2 amplified.

Image capturing Fluorescence image capturing (Mirax Scan) Brightfield image capturing (Nanozoomer) Mirax scan 150 / Panoramic NanoZoomer 2.0

Analysis of the digital images Process digital files Select analysis protocol Define TMA configuration Define tissue type or Include all information in TMA file and bar code.

Analysis of the digital images Process digital files Extract each core Run the different image analysis protocols

Analysis of the digital images Select patient Automatically retrieve all cores from this patient Mask region of interest in one core (e.g., H&E or CKA) Automatically align ROI in other cores

Analysis of the digital images Evaluate the results from the selected protocols IHC FISH ISH Link results to the patient record and consult the oncologist

Personalized Medicine

Future non invasive follow up PET/CT with FDG for follow up on treatment Fine needle biopsy for diagnose

Speciel thanks! Public Welfare Technology (ABT-fonden) (ATA-27) Herlev Hospital (Mirax Scan) Hamamatsu/DE (NanoZoomer Scan) Nordic BioSite (FISH assay) Visiopharm (Image analyse software) Tim Svenstrup Poulsen, e-mail: tisvpo01@heh.regionh.dk, phone: +45 44884000-89402